OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

To reveal more filter options, please select whether you would like to review Active or Closed projects:

Clear
Investigator: Grace Stutzmann

1 Projects | 1 Researchers | $338,985 Invested

2016

NeuroLucent, Inc

Grace Stutzmann, PhD

Ryanodine receptor inhibitors as a treatment for AD

  • Funding Amount: $338,985
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Target: Calcium Regulation
  • Status: Closed